What are the current standard first‑line systemic therapy options for an adult patient with stage IV colon cancer, including recommendations based on microsatellite instability‑high (MSI‑H) or mismatch‑repair deficient (dMMR) status versus microsatellite stable (MSS) disease?

Treatment of Stage IV Colon Cancer

For stage IV colon cancer, treatment selection is determined primarily by microsatellite instability (MSI) status: patients with MSI-H/dMMR tumors should receive first-line immunotherapy with pembrolizumab or nivolumab plus ipilimumab, while those with microsatellite stable (MSS) disease require chemotherapy doublets or triplets combined with targeted biologics based on molecular profiling.

MSI-H/dMMR Metastatic Disease (~5% of Stage IV Cases)

Immunotherapy is the standard first-line treatment for MSI-H/dMMR metastatic colon cancer, having replaced chemotherapy entirely in this molecular subtype 1, 2.

First-Line Options:

• Pembrolizumab monotherapy: The most established option with mature long-term data showing superior progression-free survival (16.5 vs 8.2 months) and overall survival compared to chemotherapy 1, 3. This represents the most validated single-agent approach with a well-characterized safety profile.

• Nivolumab plus ipilimumab: Provides the strongest evidence for dual checkpoint blockade with superior outcomes over both chemotherapy and anti-PD-1 monotherapy in randomized trials 4, 3. Recent data shows improved PFS (HR 0.58) and higher response rates (71.5% vs 55.5%) compared to pembrolizumab monotherapy 4. However, this comes at the cost of substantially higher immune-related toxicity (grade 3-4 adverse events in 15.7% vs 11.9%) 4.

Treatment Selection Algorithm for MSI-H/dMMR:

Choose nivolumab plus ipilimumab for:

• High disease burden requiring rapid tumor shrinkage
• Left-sided primary tumors
• BRAF-mutated tumors
• Patients who can tolerate and manage immune-related adverse events 4

Choose pembrolizumab monotherapy for:

• Right-sided BRAF wild-type tumors (where dual blockade shows no incremental benefit) 4
• Patients with comorbidities or concerns about immune toxicity
• When long-term safety data is prioritized 5

Critical caveat: Both regimens demonstrate survival benefits across all molecular subgroups (BRAF-mutated/wild-type, KRAS/NRAS-mutated/wild-type, right/left-sided), with pooled hazard ratios of 0.61 for PFS and 0.77 for OS compared to chemotherapy 3.

MSS/pMMR Metastatic Disease (~95% of Stage IV Cases)

For microsatellite stable disease, treatment is stratified by RAS and BRAF mutation status, with chemotherapy backbones combined with targeted biologics 1, 2.

RAS Wild-Type, Left-Sided Primary Tumors:

Preferred approach: Chemotherapy doublet (FOLFOX or FOLFIRI) plus anti-EGFR antibody (cetuximab or panitumumab) 1, 2. Anti-EGFR therapy is specifically recommended for left-sided tumors, as right-sided primaries show poor response to EGFR inhibition even when RAS wild-type 1.

RAS Wild-Type, Right-Sided Primary Tumors:

Preferred approach: Chemotherapy doublet plus bevacizumab 2. Avoid anti-EGFR antibodies in right-sided disease regardless of RAS status.

RAS-Mutated Disease (Any Primary Location):

Standard options:

• Fit patients without significant comorbidities: FOLFOXIRI (triplet chemotherapy) plus bevacizumab provides improved response rates and survival compared to FOLFIRI, but requires careful patient selection due to increased toxicity 2
• Most patients: Chemotherapy doublet (FOLFOX or FOLFIRI) plus bevacizumab 1, 2

BRAF V600E-Mutated Disease:

Preferred first-line: Chemotherapy doublet plus bevacizumab 2. For previously treated BRAF V600E-mutant disease, encorafenib plus cetuximab demonstrates superior outcomes compared to standard chemotherapy plus targeted therapy 1.

Frail or Elderly Patients:

Fluoropyrimidine monotherapy (5-FU or capecitabine) with or without bevacizumab is appropriate 2. For highly selected frail patients with left-sided RAS wild-type tumors unable to tolerate chemotherapy, single-agent anti-EGFR therapy may be considered 2.

Chemotherapy Backbone Selection

FOLFOX and FOLFIRI are equally effective; selection should be guided by toxicity profiles 2:

• FOLFOX: Choose when avoiding diarrhea and alopecia; accept peripheral neuropathy risk
• FOLFIRI: Choose when avoiding neuropathy; accept higher diarrhea risk
• CAPOX: Acceptable alternative to FOLFOX with similar efficacy
• CAPIRI: Generally avoided due to unfavorable toxicity compared to FOLFIRI unless dose-modified 2

Oligometastatic and Liver-Limited Disease

For potentially resectable liver metastases, perioperative chemotherapy or surgery alone should be offered 1. Multidisciplinary evaluation is mandatory to determine resectability and optimal sequencing of systemic therapy and surgery 1.

Key Clinical Pitfalls

1. Do not use anti-EGFR antibodies in right-sided primary tumors, even if RAS wild-type—outcomes are inferior to bevacizumab-based regimens 1, 2.

2. Do not use chemotherapy as first-line treatment for MSI-H/dMMR metastatic disease—immunotherapy provides dramatically superior outcomes and chemotherapy is now considered substandard 1, 3.

3. Do not use FOLFOXIRI in unselected patients—reserve for fit patients without comorbidities who require high response rates 2.

4. Verify MSI/MMR status before initiating any systemic therapy—this single biomarker fundamentally changes treatment strategy and should be tested universally 1, 2.

5. For MSS disease, immunotherapy (including pembrolizumab) is ineffective unless tumor mutational burden is ≥10 mutations/Mb, which is rare 1.